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PODIUM SESSION I: DEVELOPMENTS IN QUESTIONNAIRES 
EQ-5D AND SF-6D
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POPULATION
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OBJECTIVES: The new ﬁ ve-level version of the EQ-5D is now ofﬁ cially available. a 
pilot ﬁ ve-level version of EQ-5D questionnaire was successfully tested in patients with 
cancer. Other studies, using the ofﬁ cial EQ-5D-5L, in moderately or severely disabled 
populations of patients with stroke, diabetes, injury, or psychiatric conditions are 
under way. Nothing is known about how EQ-5D-5L performs in relatively young and 
healthy populations. Aim of the study was to compare a polish version of the three-
level EQ-5D questionnaire (3L) with the ﬁ ve-level version (5L) in a student population. 
METHODS: In March 2010, all students from the Faculty of Pharmacy, Medical 
University of Warsaw were surveyed with a set of HRQoL questionnaires (5L, 
EQ-VAS, SF-36, and 3L). We examined percentage of reported problems, proportion 
and size of logical inconsistencies, ceiling effect, redistribution properties, convergent 
validity with SF-36 domains, and discriminatory power using Shannon’s indices. 
RESULTS: Four hundred eighty-ﬁ ve students were approached and 443 responded to 
all questionnaires (5L, SF-36, and 3L). The domains with the highest and the lowest 
proportion of reported problems by 5L were Anxiety/Depression (57.1%) and Self-
Care (0.2%), respectively. 3L and 5L responses were highly correlated in Pain/Dis-
comfort (Pearsons’s Rho = 0.71), Usual Activities (0.64), and Anxiety/Depression 
domains (0.64). Mean rate of logical inconsistencies was 3.02%, with 93% of them 
being level 1 (according to Janssen et al., 2008). The ceiling effect was indentiﬁ ed in 
47% of 3L questionnaires and 34% of 5L questionnaires. Absolute informativity was 
higher for 5L, with similar relative informativity for both instruments. CONCLU-
SIONS: Results obtained in students support introduction of new 5-level version of 
EQ-5D in young and healthy populations. EQ-5D-5L appears to be more favorable 
in terms of ceiling effect and absolute informativity.
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OBJECTIVES: To assess the performance of the EQ-5D-5L in a naturalistic context 
targeted to patients with hepatic diseases. Preliminary investigations suggest that the 
new version of EQ-5D, with ﬁ ve levels (5L) of severity per domain, is promising to 
assess individuals’ QoL more appropriately than the standard version with three levels. 
However, further research is encouraged to investigate the EQ-5D-5L properties in 
different subpopulations and contexts. METHODS: This study was conducted within 
a project aimed to estimate costs and QoL related to hepatic diseases. The participants 
self-completed a questionnaire including the 5L descriptive system, the 3L standard 
descriptive system, and the VAS. The following properties were tested: feasibility 
(amount of missing answers); amount of inconsistent and consistent responses between 
3L and 5L versions; convergent validity with the 3L version and VAS (Spearman’s 
rank correlation coefﬁ cient); discriminatory power (informativity). RESULTS: Data 
from 426 patients were analyzed: 69% male, 19 to 84 (median = 57) years old. They 
were affected with: chronic hepatitis C (25.4%), chronic hepatitis B (22.5%), chronic 
hepatitis B and C (1.2%), cirrhosis (20.9%), liver transplantation (19.0%), hepatic 
carcinoma (4.5%), nonalcoholic steatohepatitis (1.9%), and other less frequent 
hepatic diseases. With the standard version (3L), patients reported some or severe 
problems with mobility (24.2%), self-care (10.4%), usual activities (29.0%), pain/
discomfort (35.5%), and anxiety/depression (37.4%). Median VAS was 70 (15–100). 
Missing answers were more frequent with the 3L version (6.6% vs. 4.0% of patients). 
In total, 97.5% of responses were consistent. Convergent validity of 5L-VAS (from 
−0.35 to −0.57) was similar to the one of 3L-VAS (from −0.41 to −0.56). 3L-5L cor-
relation coefﬁ cient ranged from 0.83 to 0.91. Informativity was similar between the 
two versions. CONCLUSIONS: The EQ-5D-5L version holds promise as a valid 
extension of the standard 3L version for the assessment of QoL of individuals with 
hepatic diseases.
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OBJECTIVES: The SF-6D is a preference-based measure of health developed to esti-
mate utility values from the SF-36. The aim of this study was to estimate preference 
weights for SF-6D health states representing the preferences of a sample of Southern 
Brazilian general population. METHODS: A sample of 248 health states deﬁ ned by 
the SF-6D has been valued by a sample of Southern Brazilian population using the 
standard gamble (SG) method. SG responses were used to estimate regression models 
at the individual and mean levels to predict preference values for all SF-6D health 
states. The models were compared with those described in the UK study. RESULTS: 
Five hundred twenty-eight participants were interviewed, but 146 (28%) were 
excluded due to inconsistent SG responses. Data from 382 subjects were used to 
estimate the models, rendering 2224 health states valuations. All Brazilian models have 
a large number of signiﬁ cant coefﬁ cients and a mean absolute difference between 
observed and predicted values below 0.07. Inconsistent coefﬁ cients have been merged 
to produce the ﬁ nal recommended model. Compared to UK data, Brazilian health state 
values were lower, leading to a lower constant term in the models. The best model 
ﬁ tted to Brazilian data was a random effects model using only the main effects vari-
ables, different from the preferred British SF-6D mean model, highlighting the impor-
tance to adopt a country-speciﬁ c algorithm in predicting SF-6D health states values. 
CONCLUSIONS: The results provide the ﬁ rst population-based value set for health 
states in Brazil, making it possible to generate QALYs for cost-utility studies using 
regional data. Utility scores based on Brazilian preferences values can be derived from 
existing SF-36 data sets.
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OBJECTIVES: Measurement of health-related quality of life (HRQoL) is a crucial 
aspect of cost-effectiveness analysis. Two of the most widely used instruments for 
assessing HRQoL are EQ-5D and SF-6D. Previous studies have shown that the sen-
sitivity of these instruments differ depending on the severity of the disease. However, 
few studies have systematically compared EQ-5D and SF-6D scores in a representative 
sample of the general population. The objective of this study is to describe and 
compare HRQoL derived from EQ-5D and SF-6D in a Swedish general population 
for age, gender, and seven disease groups (respiratory, tumor, endocrine, cardiovas-
cular, orthopedic, mental, and rheumatic diseases). METHODS: The EQ-5D and 
SF-6D were included in a cross-sectional postal health survey in Östergötland County 
to a representative sample (n = 6628, age: 18–84). RESULTS: When comparing 
EQ-5D and SF-6D with regard to age, the mean HRQoL with EQ-5D across all ages 
was 0.81, ranging from 0.86 (18–29 years) to 0.71 (80–84 years). For SF-6D, mean 
HRQoL for the same population was 0.74, ranging from 0.75 (18–29 years) to 0.66 
(80–84 years). With regard to gender, HRQoL was higher overall for men compared 
to women. Men had an EQ-5D score of 0.83 and a SF-6D score of 0.79; in contrast, 
women had an EQ-5D score of 0.79 and a SF-6D score of 0.73. Across disease groups, 
the mean EQ-5D scores ranged from 0.60 (rheumatic) to 0.75 (endocrine), mean 
SF-6D index values ranged from 0.64 (rheumatic) to 0.71 (endocrine). CONCLU-
SION: Although EQ-5D and SF-6D appear to measure similar constructs, our results 
show that HRQoL varies greatly among the general population depending on chosen 
instrument. However, when comparing our results across disease groups, differences 
between the instruments appear less substantial. Our ﬁ ndings could have serious 
implications for the transparency of cost-effectiveness analysis, if different studies use 
HRQoL measurements that are not equivalent. 
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OBJECTIVES: To discuss and explore important sources of structural uncertainty in 
a decision model for drug treatment in Alzheimer’s disease. Progression in Alzheimer’s 
disease can be modeled on various domains (e.g., cognition, function, behavior), each 
of which can be measured by various scales. Deﬁ ning disease progression and incor-
porating a treatment effect can therefore be difﬁ cult, requiring many assumptions 
based on little or inconsistent evidence, resulting in a great deal of structural uncer-
tainty. METHODS: We explored the impact of structural assumptions in a published 
three-state Markov model of treatment for Alzheimer’s disease. This ultimately led to 
the development of a novel model. Elements of structural uncertainty included 1) 
deﬁ ning the model states; 2) predicting occupancy of the states over time; and 3) 
allowance for disease progression within a state. RESULTS: Assessment of the step-
by-step structural changes to the published model indicated a number of assumptions 
having a relatively large impact on the cost-effectiveness results, generally resulting in 
lower costs per quality-adjusted life-year (QALY) associated with the treatments. The 
cumulative impact of these assumptions was also considerable. However, there is little 
evidence to inform which assumptions are the most realistic. CONCLUSIONS: Inves-
tigation into sources of structural uncertainty has helped to identify which assump-
tions had the largest impact on the estimated costs per QALY. However, this does 
not help to reduce the uncertainty in the decision model, but does make the structural 
uncertainty explicit. Decision-makers are therefore forced to address this type of 
uncertainty as well as parameter uncertainty. Exploring structural uncertainty also 
helps to identify gaps in the current evidence base to help understand which assump-
tions may be the most credible.
